Free Trial

Verona Pharma Q2 2024 Earnings Report

Verona Pharma logo
$41.53 -0.13 (-0.31%)
(As of 12:15 PM ET)

Verona Pharma EPS Results

Actual EPS
-$0.88
Consensus EPS
-$0.35
Beat/Miss
Missed by -$0.53
One Year Ago EPS
-$0.11

Verona Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Verona Pharma Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

Verona Pharma Earnings Headlines

Verona Pharma (VRNA) Gets a Buy from Truist Financial
Verona Pharma plc (NASDAQ:VRNA) CFO Sells $920,477.28 in Stock
Genesis leading the smart algo revolution?
I’m revealing an exciting breakthrough that can help trade the markets unlike anything you’ve ever seen before… Because with my BRAND NEW smart algo you’ll always have a constant stream of alerts firing off in your back pocket to choose from. Here’s why: It does all the heavy lifting for you… automatically. Stock Ticker, Entry Price, Profit Target, Stop Loss, and even an Individual Chart!
Jefferies Sticks to Their Buy Rating for Verona Pharma (VRNA)
See More Verona Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verona Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verona Pharma and other key companies, straight to your email.

About Verona Pharma

Verona Pharma (NASDAQ:VRNA), a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

View Verona Pharma Profile

More Earnings Resources from MarketBeat

Upcoming Earnings